Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?

Gras L, Geskus RB, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Prins JM, Berkhout B, de Wolf F; ATHENA National Observational Cohort.

PLoS One. 2013 May 27;8(5):e64437. doi: 10.1371/journal.pone.0064437. Print 2013.

2.

Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007.

Crum-Cianflone N, Eberly L, Zhang Y, Ganesan A, Weintrob A, Marconi V, Barthel RV, Fraser S, Agan BK, Wegner S.

Clin Infect Dis. 2009 May 1;48(9):1285-92. doi: 10.1086/597777.

3.

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.

PLoS One. 2012;7(3):e32369. doi: 10.1371/journal.pone.0032369. Epub 2012 Mar 6.

4.

Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in Singapore.

Ng OT, Lin L, Laeyendecker O, Quinn TC, Sun YJ, Lee CC, Leo YS.

PLoS One. 2011 Jan 27;6(1):e15738. doi: 10.1371/journal.pone.0015738.

6.

Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.

Easterbrook PJ, Yu LM, Goetghebeur E, Boag F, McLean K, Gazzard B.

AIDS. 2000 Mar 31;14(5):561-71.

PMID:
10780719
7.

Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.

Maas JJ, Dukers N, Krol A, van Ameijden EJ, van Leeuwen R, Roos MT, de Wolf F, Coutinho RA, Keet IP.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):254-9.

PMID:
9803967
8.

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.

O'Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, Lopardo G, Das S, Wood R, Wilkin A, Klinker H, Kantipong P, Klingman KL, Jilich D, Herieka E, Denning E, Abubakar I, Gordin F, Lundgren JD; INSIGHT START study group.

Lancet HIV. 2017 Mar;4(3):e105-e112. doi: 10.1016/S2352-3018(16)30216-8. Epub 2017 Jan 5.

9.

Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.

Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, Durier N, Phanuphak P, Ditangco R, Chaiwarith R, Kantipong P, Lee CK, Mustafa M, Saphonn V, Ratanasuwan W, Merati TP, Kumarasamy N, Wong WW, Zhang F, Pham TT, Pujari S, Choi JY, Yunihastuti E, Sungkanuparph S; TREAT Asia HIV Observational Databases (TAHOD); TREAT Asia Studies to Evaluate Resistance (TASER).

J Int AIDS Soc. 2014 Mar 14;17:18804. doi: 10.7448/IAS.17.1.18804. eCollection 2014.

10.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
11.

Predictors of antiretroviral therapy initiation: a cross-sectional study among Chinese HIV-infected men who have sex with men.

Liu Y, Ruan Y, Vermund SH, Osborn CY, Wu P, Jia Y, Shao Y, Qian HZ.

BMC Infect Dis. 2015 Dec 15;15:570. doi: 10.1186/s12879-015-1309-x.

12.

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.

Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber J.

AIDS. 2007 Jun 19;21(10):1283-91.

PMID:
17545704
13.

Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.

Gras L, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Lange J, Prins JM, Berkhout B, de Wolf F; ATHENA National Observational Cohort Study.

PLoS One. 2009 Oct 7;4(10):e7365. doi: 10.1371/journal.pone.0007365.

14.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
15.

No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.

Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N, Gerstoft J.

HIV Med. 2013 Jul;14(6):362-9. doi: 10.1111/hiv.12016. Epub 2013 Feb 21.

16.

Viral load and CD4 count dynamics after HIV-1 seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil.

Djomand G, Duerr A, Faulhaber JC, Struchiner CJ, Pacheco AG, Barroso PF, Melo MF, Schechter M.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):401-4.

PMID:
17031316
17.

Do gender differences in CD4 cell counts matter?

Prins M, Robertson JR, Brettle RP, Aguado IH, Broers B, Boufassa F, Goldberg DJ, Zangerle R, Coutinho RA, van den Hoek A.

AIDS. 1999 Dec 3;13(17):2361-4.

PMID:
10597777
18.

Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.

PMID:
23221982
19.

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.

Clin Infect Dis. 2011 Oct;53(8):817-25. doi: 10.1093/cid/cir494.

PMID:
21921225
20.

Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection.

Thornhill J, Inshaw J, Kaleebu P, Cooper D, Ramjee G, Schechter M, Tambussi G, Fox J, Samuel M, Miro JM, Weber J, Porter K, Fidler S.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):69-73. doi: 10.1097/QAI.0000000000001013.

Supplemental Content

Support Center